Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1 1

Status

Active not recruiting 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 4

Interventions

Pemetrexed 22Carboplatin 22Cisplatin 19Paclitaxel 9Gemcitabine 9pembrolizumab 8osimertinib 7Nivolumab 6Crizotinib 6durvalumab 5atezolizumab 5amivantamab 4Ipilimumab 4Docetaxel 4Afatinib 4tremelimumab 3lazertinib 3Vinorelbine 3Gefitinib 3Etoposide 3Albumin-Bound Paclitaxel 3trametinib 2selpercatinib 2lorlatinib 2larotrectinib 2dabrafenib 2cemiplimab 2binimetinib 2alectinib 2PM 01183 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has announcements × amivantamab × Thoracic × Clear all
NCT02609776 2026-06-05

CHRYSALIS

Janssen Research & Development, LLC

Phase 1 Active not recruiting
751 enrolled 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04487080 2026-05-08

MARIPOSA

Janssen Research & Development, LLC

Phase 3 Active not recruiting
1,074 enrolled 13 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04538664 2026-05-08

PAPILLON

Janssen Research & Development, LLC

Phase 3 Active not recruiting
308 enrolled 12 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04988295 2026-05-08

MARIPOSA-2

Janssen Research & Development, LLC

Phase 3 Active not recruiting
776 enrolled 13 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡